![McWilliams School of Biomedical Informatics](../../assets/md5images/f59dc081b7356339757ba9861fe6e1e1.jpg)
Journal Articles
Publication Date
9-19-2022
Journal
Pharmaceutics
Abstract
RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.
Keywords
oral drug delivery, siRNA, inflammatory bowel disease, gene delivery, nanomedicines, Immunotherapy
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Digestive System Diseases Commons, Gastroenterology Commons, Medical Biochemistry Commons
Comments
PMID: 36145716